Search Clinical Trials in the European Union

Duration
Visits
Phase
Injection
Benefits
Drugs
Locations
Clinical Specialty
1741-1760 of 2,120 trials

HPV-Negative Head and Neck Cancer: PARP Inhibitor and Immunotherapy Study

We are investigating a new treatment combining a PARP inhibitor and immunotherapy for patients with HPV-negative head and neck cancer. The study aims to see how well this treatment works and its safety compared to standard options.

Oropharyngeal Squamous Cell CarcinomaEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncologyOtolaryngology

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Nivolumab for ALK+ Anaplastic Large Cell Lymphoma

We are studying the effects of nivolumab in patients with relapsed or refractory ALK+ anaplastic large cell lymphoma. This trial looks at its effectiveness for those with progressive disease and as a follow-up treatment for those in remission.

Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyPediatrics

Head and Neck Cancer: Nivolumab and Ipilimumab Study

We are studying the effects of nivolumab alone and in combination with ipilimumab after surgery for head and neck cancer. This trial aims to see if these treatments can help patients stay cancer-free and how they affect quality of life.

Head and Neck Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Chronic Rhinosinusitis with Nasal Polyps: Itepekimab Study

We are investigating whether itepekimab can help adults with chronic rhinosinusitis and nasal polyps by reducing polyp size and nasal congestion. This study will also look at its effects on overall symptoms and quality of life.

Chronic Rhinosinusitis with Nasal PolypsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngologyPulmonology

CAR-T Cell Therapy for Autoimmune Diseases

We are studying a new CAR-T cell treatment for patients with active autoimmune diseases like lupus, systemic sclerosis, and inflammatory myopathy. The trial aims to assess safety and how well this therapy works in reducing disease symptoms.

Systemic SclerosisSystemic Lupus ErythematosusIdiopathic Inflammatory Myopathy6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesDermatologyNeurologyRheumatology

CD19+ Lymphoid Disease: CAR T-Cell Therapy

We are studying a new treatment using modified T cells for patients with relapsed or refractory CD19+ lymphoid diseases like leukemia and lymphoma. The goal is to see if this approach can safely reduce cancer and improve patient outcomes.

Acute Lymphoblastic Leukemia (ALL) RecurrentNon-Hodgkin's Lymphoma (NHL) Refractory>2 yearsSafety phase (I)Efficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesHematologyOncology

Triple-Negative Breast Cancer: Sacituzumab Tirumotecan Study

We are studying a new treatment for people with previously untreated triple-negative breast cancer. This trial compares a new drug alone and with another medication against standard treatment to see which works better.

Triple Negative Breast Cancer (TNBC)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

B-Cell Malignancies: MB-CART2219.1 Therapy

We are testing a new CAR T-cell therapy for adults and children with relapsed or refractory B-cell cancers. The study aims to find the right dose and evaluate its safety and effectiveness.

Relapsed/Refractory Lymphoma or ALL>2 yearsSafety phase (I)No PlaceboInvestigational MedicinesOncology

Recurrent Ovarian Cancer: Olaparib vs. Chemotherapy

We are studying whether olaparib can help patients with recurrent ovarian cancer live longer without disease progression after surgery, compared to standard chemotherapy. The trial also looks at safety and quality of life.

Recurrent Ovarian CancerConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteOncology

Patent Ductus Arteriosus: Paracetamol Treatment in Premature Infants

We are studying whether early treatment with Paracetamol helps extremely low birth weight infants with Patent Ductus Arteriosus avoid serious complications. This trial compares the effects of Paracetamol to a placebo.

Patent Ductus Arteriosus≤3 monthsConfirmation phase (III)Investigational MedicinesCardiologyPediatrics

Allergic Rhinitis: Beltavac® Immunotherapy

We are studying the effectiveness and safety of Beltavac®, a new immunotherapy, for people with allergic rhinitis caused by house dust mites. The trial will also look at how it affects allergy symptoms and overall quality of life.

House Dust Mite Allergy>2 yearsConfirmation phase (III)Investigational MedicinesAllergologyOphthalmologyOtolaryngology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Diffuse Large B-Cell Lymphoma: Polatuzumab Vedotin with R-CHP

We are studying whether a new treatment combining polatuzumab vedotin with standard chemotherapy helps patients with diffuse large B-cell lymphoma live longer without disease progression compared to the current standard treatment.

Diffuse Large B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOncology

Solid Tumors: Valemetostat Tosylate with DXd ADCs

We are studying a new combination treatment for patients with solid tumors to evaluate its safety and effectiveness. This trial aims to find better options for managing cancer.

Solid TumorSafety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesOncology

SAPHO Syndrome: Etanercept Treatment Study

We are testing the safety and effectiveness of etanercept in patients with SAPHO syndrome who are already on standard treatments. This study aims to explore new treatment options for better management of their condition.

SAPHO Syndrome6-12 monthsEfficacy phase (II)Confirmation phase (III)Standard MedicinesInfectious DiseasesRheumatology

Neovascular Age-Related Macular Degeneration: Port Delivery System with Ranibizumab

We are studying a new delivery system for ranibizumab in patients with neovascular age-related macular degeneration. The goal is to see how well it works and how it affects patients' treatment experiences.

Neovascular Age-Related Macular Degeneration1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOphthalmology

Lymphoma Treatment: Loncastuximab Tesirine

We are studying a new treatment for patients with relapsed or refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma after CAR T-cell therapy. The goal is to see if it improves response rates and survival outcomes.

B-cell Non-Hodgkin's Lymphoma>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology

ALS and TIA: Hyperpolarized Pyruvate MRI Study

We are testing a new MRI method to see if it can help identify metabolic problems in patients with Amyotrophic Lateral Sclerosis and Transient Ischemic Attack. This may improve our understanding of these conditions.

Amyotrophic Lateral Sclerosis (ALS)Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

Monalizumab for Acute Myeloid Leukemia and Myelodysplastic Syndrome

We are studying the safety and effectiveness of Monalizumab in patients with acute myeloid leukemia or myelodysplastic syndrome receiving a stem cell transplant. This trial aims to understand its impact on recovery and survival.

Acute Myeloid Leukemia1-2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesHematologyOncology